Jackson Laboratory scientists developed a cocktail of non-neutralizing antibodies targeting influenza A virus (IAV) that demonstrated protection across nearly all tested flu strains, including pandemic threats like H5 and H7 avian flu, in immunocompromised mice. This approach stimulates immune clearance by tagging infected lung cells rather than neutralizing viruses directly, extending the therapeutic window and potentially reshaping flu treatment paradigms with broader, long-lasting efficacy.